P3 Health Partners Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2024. The filing covers Q1 2024, notwithstanding the request metadata indicating Q1 2023. P3 is a physician-led population health company, with most revenue from at-risk Medicare Advantage capitation contracts.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Operating revenue | $388.5 million | $302.1 million | Up 29% |
| Operating loss | $43.8 million | $48.8 million | Loss narrowed |
| Net loss | $49.6 million | $52.4 million | Loss narrowed |
| Net loss attributable to controlling interest | $18.7 million | $9.2 million | Loss widened |
| Adjusted EBITDA loss | $19.8 million | $19.1 million | Loss widened |
| Net cash used in operating activities | $20.0 million | $23.7 million | Cash use decreased |
Capitated revenue was $384.1 million, about 99% of total revenue. Management attributed its growth primarily to at-risk membership increasing 23% to approximately 126,800, expansion into nine additional counties effective January 1, 2024, and a 5% increase in capitation rates. Other patient service revenue was $4.4 million.
Medical expense increased 34% to $382.1 million, faster than revenue growth. The company’s non-GAAP medical margin—capitated revenue less medical claims expense—was $36.6 million versus $39.2 million a year earlier; as a share of capitated revenue, it declined to about 9.5% from 13.1%. GAAP gross profit was $6.4 million, down from $16.5 million. Corporate, general and administrative expense fell 27% to $27.4 million, and the premium deficiency reserve expense fell to $1.0 million from $5.1 million. Q1 2024 capitation revenue included a $7.7 million release of a prior-period constraint on 2023 risk-adjustment revenue.
Liquidity, debt and balance sheet
At March 31, 2024, unrestricted cash was $27.3 million and restricted cash was $5.0 million. Cash and restricted cash together declined to $32.3 million from $40.9 million at year-end. Operating cash outflow was $20.0 million; financing provided $11.4 million, including the initial $10.0 million draw under a new VGS 2 note. Investing cash flow was zero.
Long-term debt, net, was $118.1 million and short-term debt was $1.4 million. The long-term debt included a $65.0 million term loan at 12%, a $29.1 million unsecured note at 14%, a $15.0 million repurchase note accruing PIK interest at 11%, and the initial $10.0 million VGS 2 borrowing. VGS 2 permits up to $25.0 million; the remaining $15.0 million was drawn on April 5, 2024. Its stated rate is 17.5%, and subordination terms effectively require interest to be paid in kind. Management reported covenant compliance at quarter-end but cautioned that future compliance is not assured.
Management concluded that existing cash resources are insufficient to fund planned operations for at least one year from issuance of the financial statements; substantial doubt therefore exists about the company’s ability to continue as a going concern. It is seeking additional debt and/or equity financing, with no assurance financing will be available on acceptable terms. Failure to obtain funding could require curtailing planned activities.
Outlook, risks and unusual matters
- Management expects operating losses and negative operating cash flows to continue for the foreseeable future; the filing provides no numerical earnings or revenue guidance.
- Growth, medical-cost management, membership maturity and access to capital are key factors affecting future performance. The company operates in 27 county markets across five states, with approximately 2,900 affiliate primary care physicians.
- Four health plan customers each represented at least 10% of revenue in the quarter; together, those customers represented 61% of revenue, creating customer concentration exposure. The company also depends on third-party reimbursement and Medicare Advantage contracts, and faces healthcare regulatory, medical-cost and plan-rating risks.
- Disclosure controls were deemed ineffective as of March 31, 2024 because previously identified material weaknesses in financial reporting controls remained unresolved, including controls over claims estimates, financial close, management review and IT access. Remediation is ongoing and has not yet been established as effective.
- A Delaware court trial concerning surviving claims in the Hudson dispute was scheduled to begin July 22, 2024. The company said it could not currently estimate certain reasonably possible contingencies and believes disposition of the matters will not materially affect its financial position, net loss or cash flows.
- The company recorded a $2.1 million income tax provision. Its estimated Tax Receivable Agreement liability was $11.0 million, but no TRA liability was recorded because payments were not considered probable given its history of losses.
Key facts for investors to verify
- Whether P3 obtains sufficient additional capital to address the disclosed going-concern doubt, and the financing’s cost, covenants and dilution.
- Whether medical costs and claims payable develop as estimated, and whether medical margin stabilizes as membership grows.
- Whether the company maintains compliance with debt covenants and can service high-interest debt, including PIK accruals.
- Whether the $7.7 million risk-adjustment revenue release and other estimates are supported by final payor and CMS reconciliations.
- Progress and testing results for remediation of internal-control material weaknesses, and developments in the Hudson litigation.